X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (282) 282
life sciences & biomedicine (268) 268
humans (217) 217
oncology (207) 207
male (153) 153
female (149) 149
aged (139) 139
middle aged (132) 132
colorectal cancer (117) 117
colorectal neoplasms - drug therapy (93) 93
adult (89) 89
metastasis (84) 84
antineoplastic combined chemotherapy protocols - therapeutic use (80) 80
cancer (80) 80
chemotherapy (80) 80
colorectal neoplasms - pathology (71) 71
treatment outcome (69) 69
prognosis (53) 53
aged, 80 and over (51) 51
bevacizumab (51) 51
care and treatment (51) 51
metastases (51) 51
patients (51) 51
camptothecin - analogs & derivatives (50) 50
colorectal neoplasms - genetics (49) 49
neoplasm metastasis (46) 46
fluorouracil - administration & dosage (44) 44
colorectal carcinoma (41) 41
disease-free survival (40) 40
tumors (40) 40
clinical trials (38) 38
retrospective studies (38) 38
antineoplastic combined chemotherapy protocols - adverse effects (35) 35
camptothecin - administration & dosage (35) 35
research (35) 35
survival (35) 35
colorectal neoplasms - mortality (34) 34
leucovorin - administration & dosage (33) 33
survival analysis (33) 33
metastatic colorectal cancer (32) 32
mutation (32) 32
pharmacology & pharmacy (32) 32
cetuximab (31) 31
antineoplastic combined chemotherapy protocols - administration & dosage (30) 30
cancer therapies (30) 30
antineoplastic agents - therapeutic use (29) 29
analysis (28) 28
neoplasm staging (27) 27
drug therapy (26) 26
irinotecan (24) 24
drug administration schedule (23) 23
cancer patients (22) 22
disease progression (22) 22
genetic aspects (22) 22
hematology, oncology and palliative medicine (22) 22
organoplatinum compounds - administration & dosage (22) 22
5-fluorouracil (21) 21
adenocarcinoma - drug therapy (21) 21
health aspects (21) 21
high level architecture (21) 21
oxaliplatin (21) 21
abridged index medicus (20) 20
liver neoplasms - secondary (20) 20
medicine & public health (20) 20
antibodies, monoclonal, humanized (19) 19
deoxycytidine - analogs & derivatives (19) 19
fluorouracil - therapeutic use (19) 19
kaplan-meier estimate (19) 19
medical prognosis (19) 19
polymorphism, single nucleotide (19) 19
survival rate (19) 19
settore med/06 - oncologia medica (18) 18
biomarkers (17) 17
camptothecin - therapeutic use (17) 17
liver neoplasms - drug therapy (17) 17
prospective studies (17) 17
proto-oncogene proteins p21 (17) 17
ras proteins - genetics (17) 17
receptor, epidermal growth factor - antagonists & inhibitors (17) 17
risk factors (17) 17
surgery (17) 17
angiogenesis (16) 16
patient outcomes (16) 16
proto-oncogene proteins - genetics (16) 16
proto-oncogene proteins b-raf - genetics (16) 16
usage (16) 16
vascular endothelial growth factor (16) 16
antibodies, monoclonal - administration & dosage (15) 15
fluorouracil - adverse effects (15) 15
follow-up studies (15) 15
general & internal medicine (15) 15
lung neoplasms - drug therapy (15) 15
medical research (15) 15
medicine, general & internal (15) 15
multivariate analysis (15) 15
single-nucleotide polymorphism (15) 15
biomarkers, tumor - genetics (14) 14
deoxycytidine - administration & dosage (14) 14
digestive system diseases (14) 14
leucovorin - therapeutic use (14) 14
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The lancet oncology, ISSN 1470-2045, 10/2015, Volume 16, Issue 13, pp. 1306 - 1315
Summary Background In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab significantly improved... 
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Leucovorin - administration & dosage | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Bevacizumab - therapeutic use | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Angiogenesis Inhibitors - administration & dosage | Neoplasm Metastasis | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Time Factors | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Angiogenesis Inhibitors - therapeutic use | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Bevacizumab - administration & dosage | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Intention to Treat Analysis | Italy | Aged | Infusions, Intravenous | Mutation | Colorectal Neoplasms - pathology | Antimitotic agents | Cancer patients | Care and treatment | Patient outcomes | Analysis | Colorectal cancer | Leucovorin | Metastasis | Antineoplastic agents | Index Medicus
Journal Article
Journal Article
Journal Article
The lancet oncology, ISSN 1470-2045, 08/2015, Volume 16, Issue 8, pp. 937 - 948
Summary Background Tumour mutational status is an important determinant of the response of metastatic colorectal cancer to targeted treatments. However, the... 
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Predictive Value of Tests | Proto-Oncogene Proteins p21(ras) | Colorectal Neoplasms - genetics | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Clinical Trials, Phase III as Topic | Time Factors | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Real-Time Polymerase Chain Reaction | Precision Medicine | Receptor, TIE-1 - blood | Phosphatidylinositol 3-Kinases - blood | Genetic Predisposition to Disease | Adenocarcinoma - blood | ras Proteins - blood | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Disease Progression | Phenotype | Class I Phosphatidylinositol 3-Kinases | Biomarkers, Tumor - genetics | ras Proteins - genetics | Patient Selection | DNA, Neoplasm - blood | Female | Adenocarcinoma - genetics | Retrospective Studies | Pyridines - therapeutic use | Colorectal Neoplasms - mortality | Colorectal Neoplasms - blood | Kaplan-Meier Estimate | Proportional Hazards Models | Phenylurea Compounds - therapeutic use | Proto-Oncogene Proteins B-raf - blood | Proto-Oncogene Proteins - genetics | Treatment Outcome | Randomized Controlled Trials as Topic | Biomarkers, Tumor - blood | Phosphatidylinositol 3-Kinases - genetics | Disease-Free Survival | Proto-Oncogene Proteins B-raf - genetics | Aged | DNA, Neoplasm - genetics | Colorectal Neoplasms - pathology | Proto-Oncogene Proteins - blood | Adenocarcinoma - mortality | Medical colleges | Medical research | Cancer patients | Prognosis | Liver | DNA | Colorectal cancer | Genetic research | Medicine, Experimental | Metastasis | Index Medicus | Life Sciences | Human health and pathology
Journal Article
Nature medicine, ISSN 1546-170X, 06/2015, Volume 21, Issue 7, pp. 795 - 801
Journal Article
The New England journal of medicine, ISSN 1533-4406, 05/2015, Volume 372, Issue 20, pp. 1909 - 1919
Journal Article
The New England journal of medicine, ISSN 1533-4406, 10/2014, Volume 371, Issue 17, pp. 1609 - 1618
In patients with metastatic colon cancer, fluorouracil, oxaliplatin, and irinotecan plus bevacizumab, as compared with fluorouracil and irinotecan plus... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Bevacizumab | Fluorouracil - therapeutic use | Antibodies, Monoclonal, Humanized - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Neoplasm Metastasis - drug therapy | Colorectal Neoplasms - drug therapy | Adult | Female | Leucovorin - therapeutic use | Liver Neoplasms - secondary | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Camptothecin - therapeutic use | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Colorectal Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Organoplatinum Compounds - adverse effects | Treatment outcome | Care and treatment | Analysis | Colorectal cancer | Dosage and administration | Leucovorin | Fluorouracil | Colorectal carcinoma | Diarrhea | Metastasis | Survival | Patients | Clinical outcomes | Metastases | Irinotecan | Stomatitis | Chemotherapy | Neurotoxicity | Oxaliplatin | Monoclonal antibodies | Vascular endothelial growth factor | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 9, pp. 845 - 852